• Detailed Phase 2 Data for Novel Alzheimer's Drug Released

    7 monthes ago - By Medscape

    While topline results from TRAILBLAZER-ALZ showed a 32% slowing of cognitive decline with the anti-amyloid drug donanemab, highly anticipated phase 2 findings provide a more detailed analysis.
    Medscape Medical News
    Read more ...

     

  • Novel Anti-Amyloid Slows Cognitive Decline in Phase II Alzheimer Trial

    Novel Anti-Amyloid Slows Cognitive Decline in Phase II Alzheimer Trial

    7 monthes ago - By MedPageToday

    Donanemab, an investigational agent targeting a specific form of beta-amyloid known as pyroglutamate-3, slowed decline in patients with early symptoms of Alzheimer's disease in the phase II TRAILBLAZER-ALZ trial, now published...
    Read more ...